Short Interest in Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Grows By 130.8%

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 4,921 shares, a growth of 130.8% from the April 15th total of 2,132 shares. Currently, 2.6% of the shares of the company are sold short. Based on an average trading volume of 2,702 shares, the short-interest ratio is currently 1.8 days.

Insider Transactions at Bitwise MARA Option Income Strategy ETF

In related news, insider Helen Louise Collins sold 40,000 shares of the firm’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $35.10, for a total value of $1,404,000.00. Following the completion of the transaction, the insider owned 25,000 shares in the company, valued at $877,500. This trade represents a 61.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 50,000 shares of company stock valued at $1,781,150. Company insiders own 37.30% of the company’s stock.

Bitwise MARA Option Income Strategy ETF Stock Performance

IMRA stock traded down $0.75 during midday trading on Friday, reaching $16.59. The stock had a trading volume of 2,855 shares, compared to its average volume of 5,498. The stock has a market cap of $3.15 million, a PE ratio of 331.80 and a beta of 3.28. The firm has a fifty day simple moving average of $14.70 and a two-hundred day simple moving average of $17.27. Bitwise MARA Option Income Strategy ETF has a 52-week low of $11.99 and a 52-week high of $60.73.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.